Daisuke Sano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6074002/publications.pdf Version: 2024-02-01



DAISLIKE SANO

#	Article	IF	CITATIONS
1	A risk factor for newly diagnosed secondary cancer in patients with early-stage laryngeal, oropharyngeal, or hypopharyngeal cancer: sub-analysis of a prospective observation study. International Journal of Clinical Oncology, 2022, 27, 488-494.	1.0	2
2	Systemic therapy for salivary gland malignancy: current status and future perspectives. Japanese Journal of Clinical Oncology, 2022, 52, 293-302.	0.6	12
3	Human papillomavirus-related oropharyngeal carcinoma. Japanese Journal of Clinical Oncology, 2022, 52, 700-706.	0.6	1
4	Partial Substitution of Glucose with Xylitol Prolongs Survival and Suppresses Cell Proliferation and Glycolysis of Mice Bearing Orthotopic Xenograft of Oral Cancer. Nutrients, 2022, 14, 2023.	1.7	0
5	Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. International Journal of Clinical Oncology, 2021, 26, 494-506.	1.0	40
6	The incidence of newly diagnosed secondary cancer; sub-analysis the prospective study of the second-look procedure for transoral surgery in patients with T1 and T2 head and neck cancer. International Journal of Clinical Oncology, 2021, 26, 59-65.	1.0	6
7	Pathogenic Role of Immune Evasion and Integration of Human Papillomavirus in Oropharyngeal Cancer. Microorganisms, 2021, 9, 891.	1.6	4
8	Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. International Journal of Clinical Oncology, 2021, 26, 1049-1056.	1.0	4
9	Treatment outcomes of transoral robotic and non-robotic surgeries to treat oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma: A multi-center retrospective observational study in Japan. Auris Nasus Larynx, 2021, 48, 502-510.	0.5	12
10	Validation of the risk factors for primary control of early T-stage laryngeal, oropharyngeal, and hypopharyngeal squamous cell carcinoma by transoral surgery: a prospective observational study. International Journal of Clinical Oncology, 2021, 26, 1995-2003.	1.0	2
11	Establishment of <scp>PDX</scp> â€derived salivary adenoid cystic carcinoma cell lines using organoid culture method. International Journal of Cancer, 2021, 148, 193-202.	2.3	16
12	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology, 2021, 51, 173-179.	0.6	15
13	Combination of Performance Status and Lymphocyte-monocyte Ratio as a Novel Prognostic Marker for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer Diagnosis & Prognosis, 2021, 1, 353-361.	0.3	2
14	Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. International Journal of Clinical Oncology, 2021, 27, 95.	1.0	7
15	Current Status of Transoral Surgery for Patients With Early-Stage Pharyngeal and Laryngeal Cancers in Japan. Frontiers in Oncology, 2021, 11, 804933.	1.3	4
16	Sphenoid sinus development in patients with acquired middle ear cholesteatoma. Auris Nasus Larynx, 2020, 47, 391-400.	0.5	2
17	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. Biochemical and Biophysical Research Communications, 2020, 522, 931-938.	1.0	5
18	Immunotherapy for squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology, 2020, 50, 1089-1096.	0.6	39

#	Article	IF	CITATIONS
19	Longâ€ŧerm treatment outcome of type 1 thyroplasty using novel titanium medialization laryngoplasty implant combined with arytenoid adduction for unilateral vocal cord paralysis: singleâ€arm interventional study at a single institution. Laryngoscope Investigative Otolaryngology, 2020, 5, 895-902.	0.6	9
20	Optimization of therapeutic strategy for p16â€positive oropharyngeal squamous cell carcinoma: Multiâ€institutional observational study based on the national Head and Neck Cancer Registry of Japan. Cancer, 2020, 126, 4177-4187.	2.0	19
21	A prospective clinical trial of the secondâ€look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer. Cancer Medicine, 2019, 8, 7197-7206.	1.3	8
22	Addition of S-1 to radiotherapy for treatment of T2N0 glottic cancer: Results of the multiple-center retrospective cohort study in Japan with a propensity score analysis. Oral Oncology, 2019, 99, 104454.	0.8	2
23	Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan. Anticancer Research, 2019, 39, 6819-6827.	0.5	21
24	The advantages and limitations of animal models of head and neck cancers. Japanese Journal of Head and Neck Cancer, 2019, 45, 366-368.	0.0	0
25	Pretreatment prognostic factor for patients with human papillomavirus related oropharyngeal cancer. Translational Cancer Research, 2019, 8, 354-356.	0.4	3
26	Prediction of the Oral Intake with an Endoscopic Swallowing Examination in Dysphagia Patients Who Underwent Surgery for Digestive Diseases. Journal of Otolaryngology of Japan, 2019, 122, 1304-1313.	0.1	0
27	Predictive value of the Hyodo score in endoscopic evaluation of aspiration during swallowing. Auris Nasus Larynx, 2018, 45, 1214-1220.	0.5	37
28	Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma. Auris Nasus Larynx, 2018, 45, 846-853.	0.5	19
29	Cochlear volume as a predictive factor for residual-hearing preservation after conventional cochlear implantation. Acta Oto-Laryngologica, 2018, 138, 345-350.	0.3	17
30	The applicability of new TNM classification for humanpapilloma virus-related oropharyngeal cancer in the 8th edition of the AJCC/UICC TNM staging system in Japan: A single-centre study. Auris Nasus Larynx, 2018, 45, 558-565.	0.5	18
31	Fibrinogen and Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hypopharyngeal Squamous Cell Carcinoma. Anticancer Research, 2018, 38, 5321-5330.	0.5	15
32	Dihydropyrimidine dehydrogenase overexpression correlates with potential resistance to 5-fluorouracil-based treatment in head and neck squamous cell carcinoma. Translational Cancer Research, 2018, 7, 411-419.	0.4	5
33	Analysis of prognostic factors, including the incidence of second primary cancer, in patients with early stage laryngeal squamous cell carcinoma treated by radiation-based therapy. Translational Cancer Research, 2018, 7, 890-900.	0.4	2
34	Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum–Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial. JMIR Research Protocols, 2018, 7, e11003.	0.5	3
35	Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan. Cancer Chemotherapy and Pharmacology, 2017, 80, 203-207.	1.1	9
36	Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPVâ€associated head and neck squamous cell carcinoma cell lines. International Journal of Cancer, 2017, 140, 1571-1580.	2.3	21

#	Article	IF	CITATIONS
37	Surgery-based versus radiation-based treatment strategy for a high metabolic volume laryngeal cancer. Laryngoscope, 2017, 127, 862-867.	1.1	9
38	A Case of Intraorbital Abscess Developing as a Complication of Acute Dacryocystitis. Journal of Otolaryngology of Japan, 2017, 120, 722-726.	0.1	0
39	The Second-Look Procedure for Transoral Videolaryngoscopic Surgery for T1 and T2 Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer Patients: Protocol for a Nonrandomized Clinical Trial. JMIR Research Protocols, 2017, 6, e235.	0.5	5
40	Prognostic significance of metabolic tumor volume in patients with piriform sinus carcinoma treated by radiotherapy with or without concurrent chemotherapy. Head and Neck, 2016, 38, 1666-1671.	0.9	6
41	Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 1315-1319.	1.1	7
42	The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. International Journal of Clinical Oncology, 2016, 21, 819-826.	1.0	60
43	JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2016, 35, 6.	3.5	51
44	Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with salvage surgery after concurrent chemoradiotherapy. International Journal of Clinical Oncology, 2016, 21, 869-874.	1.0	39
45	Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma. International Journal of Clinical Oncology, 2016, 21, 658-667.	1.0	18
46	Reduction surgery using a combination of a stereolithographic model and navigation system for ossifying fibroma with secondary central giant cell granuloma. Auris Nasus Larynx, 2016, 43, 207-211.	0.5	5
47	Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy. International Journal of Clinical Oncology, 2016, 21, 224-230.	1.0	6
48	Predictive and Prognostic Value of Metabolic Tumor Volume (MTV) in Patients with Laryngeal Carcinoma Treated by Radiotherapy (RT) / Concurrent Chemoradiotherapy (CCRT). PLoS ONE, 2015, 10, e0117924.	1.1	23
49	An Aerodynamic Study of Phonations in Patients With Parkinson Disease (PD). Journal of Voice, 2015, 29, 273-280.	0.6	16
50	Evolutionary Action Score of <i>TP53</i> Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Research, 2015, 75, 1527-1536.	0.4	139
51	STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e81819.	1.1	22
52	HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck, 2014, 36, 1547-1554.	0.9	31
53	Telomeraseâ€specific oncolytic adenovirus: Antitumor effects on radiationâ€resistant head and neck squamous cell carcinoma cells. Head and Neck, 2014, 36, 411-418.	0.9	8
54	Phase II Study of Concurrent Chemoradiotherapy with S-1 in Patients with Stage II (T2N0M0) Squamous Cell Carcinoma of the Pharynx or Larynx. Japanese Journal of Clinical Oncology, 2014, 44, 1158-1163.	0.6	9

#	Article	IF	CITATIONS
55	To "Grow―or "Go― TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCH Clinical Cancer Research, 2014, 20, 4673-4688.	N. _{3.2}	86
56	Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy. Cancer Chemotherapy and Pharmacology, 2014, 73, 1147-1154.	1.1	19
57	Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. Molecular Cell, 2014, 54, 960-974.	4.5	196
58	Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head and Neck, 2013, 35, 321-328.	0.9	14
59	Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncology, 2013, 49, 761-770.	0.8	26
60	Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Cancer Chemotherapy and Pharmacology, 2013, 72, 837-843.	1.1	11
61	Serine substitution of proline at codon 151 ofTP53confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope, 2013, 123, 1416-1423.	1.1	25
62	Noncovalent Assembly of Targeted Carbon Nanovectors Enables Synergistic Drug and Radiation Cancer Therapy <i>in Vivo</i> . ACS Nano, 2012, 6, 2497-2505.	7.3	26
63	Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma. Anticancer Research, 2012, 32, 595-600.	0.5	19
64	Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head and Neck, 2011, 33, 349-358.	0.9	22
65	Noncovalent Functionalization of Carbon Nanovectors with an Antibody Enables Targeted Drug Delivery. ACS Nano, 2011, 5, 6643-6650.	7.3	45
66	Hyaluronic acid–paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncology, 2011, 47, 1039-1047.	0.8	32
67	Disruptive <i>TP53</i> Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer. Clinical Cancer Research, 2011, 17, 6658-6670.	3.2	94
68	Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model. Clinical Cancer Research, 2011, 17, 2281-2291.	3.2	68
69	Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites. Clinical Cancer Research, 2011, 17, 7248-7264.	3.2	230
70	Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <i>In Vivo</i> and <i>In Vitro</i> . Clinical Cancer Research, 2011, 17, 1815-1827.	3.2	76
71	IL-6 Stabilizes Twist and Enhances Tumor Cell Motility in Head and Neck Cancer Cells through Activation of Casein Kinase 2. PLoS ONE, 2011, 6, e19412.	1.1	73
72	Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma <i>In vivo</i> and Synergizes with Chemotherapy. Clinical Cancer Research, 2010, 16, 1834-1844.	3.2	115

#	Article	IF	CITATIONS
73	Effective Drug Delivery, <i>In Vitro</i> and <i>In Vivo</i> , by Carbon-Based Nanovectors Noncovalently Loaded with Unmodified Paclitaxel. ACS Nano, 2010, 4, 4621-4636.	7.3	85
74	The Effect of Combination Anti–Endothelial Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis. JAMA Otolaryngology, 2009, 135, 411.	1.5	22
75	Xenograft models of head and neck cancers. Head & Neck Oncology, 2009, 1, 32.	2.3	89
76	Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model. Clinical Cancer Research, 2008, 14, 5081-5089.	3.2	23
77	Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma. Oncology Reports, 2008, 20, 1363-8.	1.2	6
78	Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncology Reports, 2007, 18, 47.	1.2	22
79	Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma. Auris Nasus Larynx, 2007, 34, 487-491.	0.5	15
80	Metastasis of squamous cell carcinoma of the oral tongue. Cancer and Metastasis Reviews, 2007, 26, 645-662.	2.7	317
81	Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncology Reports, 2007, 17, 289-95.	1.2	28
82	Maxillary sinus carcinoma: The only symptom was neck lymph node swelling. Auris Nasus Larynx, 2006, 33, 57-61.	0.5	5
83	Myxofibrosarcoma of the hypopharynx. Auris Nasus Larynx, 2006, 33, 93-96.	0.5	31
84	A case of metastatic colon adenocarcinoma in the larynx. Acta Oto-Laryngologica, 2005, 125, 220-222.	0.3	19
85	Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncology Reports, 0, , .	1.2	7